XS
REGN icon

XR Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

XR Securities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-672
Closed -$706K – 140
2024
Q3 		$706K Buy
672
+20
+3% +$22.3K 0.21% 87
2024
Q2 		$685K Sell
652
-229
-26% -$222K 0.13% 125
2024
Q1 		$848K Sell
881
-3,126
-78% -$2.97M 0.03% 159
2023
Q4 		$3.52M Buy
4,007
+3,584
+847% +$2.95M 0.13% 68
2023
Q3 		$348K Buy
+423
New +$332K 0.03% 296
2020
Q2 		– Sell
-426
Closed -$242K – 295
2020
Q1 		$208K Buy
+426
New +$176K 0.02% 120
2019
Q3 		– Sell
-2,255
Closed -$706K – 308
2019
Q2 		$706K Buy
2,255
+1,299
+136% +$432K 0.14% 46
2019
Q1 		$393K Buy
+956
New +$394K 0.05% 94

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

XR Securities's REGN Position: Q4 2024 in Review

XR Securities sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 672 shares — an estimated $706K sold.

XR Securities first reported a position in REGN in Q1 2019 and held it in 8 quarters. The position peaked at $3.52M in Q4 2023. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • XR Securities reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • XR Securities sold 672 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $706K.
  • XR Securities first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 8 quarters.
  • XR Securities's Regeneron Pharmaceuticals position peaked at $3.52M in Q4 2023.
  • 1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on XR Securities's 13F filing for Q4 2024, filed 17 Jan 2025.